NEW YORK (GenomeWeb) – Israeli epigenetics-based diagnostics firm Nucleix announced today that it has completed a $3 million private financing round. 

Nucleix said that the proceeds of the round will be used to complete the clinical studies required for US Food and Drug Administration approval of its urine-based bladder cancer test Bladder EpiCheck, and to begin marketing efforts for the test in Europe. The company also said that it would use the money to expand its 16-employee workforce.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.